Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eprenetapopt + Dabrafenib in Resistant Melanoma
NCT03391050Phase 2Terminated
- Sponsor
- Aprea Therapeutics
- Start
- Jan 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eprenetapopt in cutaneous melanoma (CM), sponsored by Aprea Therapeutics. Started Jan 2018; status: terminated.
02
Drugs
eprenetapopt
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT03391050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03391050.